Drug intelligence / Profile preview

MACF1 CRISPR-Cas9

Development stage: Preclinical
Lead developer: Tennessee State University
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies

Overview

MACF1 CRISPR-Cas9 is a genome editing tool designed to inhibit the expression of Microtubule Actin Crosslinking Factor 1 (MACF1), a spectraplakin protein that cross-links microtubules and actin filaments. MACF1 is highly expressed in glioblastoma tissue and is associated with resistance to chemotherapy. By utilizing the CRISPR-Cas9 system to knock out or inhibit MACF1, researchers aim to sensitize glioblastoma cells to treatment with BCNU (carmustine), potentially serving as a neoadjuvant approach to improve therapeutic outcomes in brain cancer.

Other names: MACF1 CRISPR inhibitionMACF-1 CRISPR inhibitionMACF 1 CRISPR inhibition

Beyond the preview

Go deeper on MACF1 CRISPR-Cas9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MACF1 CRISPR-Cas9.

Explore the full profile